Disease specific news: EU gives backing to hepatitis B Viread
28 Apr 2008

The European Commission has given its approval to the marketing of Viread (tenofovir disoproxil fumarate) as a treatment for chronic hepatitis B.

Viread has received approval for use across the EU's 27 member states for compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

Drug maker Gilead said that the decision for approval was based primarily on results from two ongoing Phase III trials investigating the safety, tolerability and efficacy of the drug compared to Hepsera (adefovir dipivoxil).

"Viread has many of the preferred qualities of an antiviral treatment: rapid and profound viral suppression, a well-established safety profile with more than one million years of patient experience, and convenient once-daily administration," Kevin Young, executive vice president at Gilead Sciences said.

"Now that Viread is approved for chronic hepatitis B in Europe, our top priority is working to ensure that all individuals who need the medication have access to it as quickly as possible," he added.

Applications for the drug are currently pending in the US, Canada and Australia.

Click here for EPG Online physician's tools including disease awareness, diagnosis tools, treatment options and management guidance

Print Article    Bookmark

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...